Menopause Linked to Significant Lung Function Decline Regardless of HIV Status

As the life expectancy of women living with human immunodeficiency virus (HIV) continues to improve, clinicians are increasingly tasked with managing the complex intersection of chronic viral infection and reproductive aging [1, 2]. Data from the REPRIEVE trial involving 1,449 women with HIV indicate that advanced reproductive age is significantly associated with metabolic dysregulation, including a waist circumference greater than 88 cm (odds ratio 1.38; 95% confidence interval, 1.06 to 1.80) [2]. While clinical attention during the menopausal transition often focuses on cardiovascular risk and metabolic syndrome (a cluster of conditions including hypertension and dyslipidemia) [3, 4], the systemic impact of estrogen depletion may extend to the pulmonary system. Chronic inflammation and immune activation, characterized by the dysregulated synthesis of interleukin 6 (a signaling protein that triggers systemic inflammatory responses), potentially exacerbate physiological declines in organ function [5]. Despite these risks, current HIV management guidelines lack specific protocols for monitoring respiratory health, and several general menopause resources have recently been archived as outdated [1, 6]. To address this gap, researchers recently analyzed how specific menopausal stages correlate with objective measures of lung function, providing data that could help physicians better anticipate respiratory decline in aging female patients.